Resource Summary Report

Generated by RRID on Aug 21, 2026

pHL-EF1a-SphcCas9-iP-A

RRID:Addgene_60599
Type: Plasmid

Proper Citation

RRID:Addgene_60599

Plasmid Information

URL: http://www.addgene.org/60599

Proper Citation: RRID:Addgene_60599

Insert Name: CRISPR Cas9

Organism: Streptococcus pyogenes

Bacterial Resistance: Ampicillin

Defining Citation: PMID:25434822

Vector Backbone Description: Backbone Marker:Hotta Lab, CiRA; Backbone Size:6923; Vector Backbone:pHL-EF1a-GW-iP-A; Vector Types:Mammalian Expression, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: pHL-EF1a-SphcCas9-iP-A

Relevant Mutation: Codon usage optimized for human usage

Record Creation Time: 20220422T222348+0000

Record Last Update: 20260815T081734+0000

Ratings and Alerts

No rating or validation information has been found for pHL-EF1a-SphcCas9-iP-A.

No alerts have been found for pHL-EF1a-SphcCas9-iP-A.

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Park SB, et al. (2026) Human pluripotent stem cell engineering with CRISPR-Cas9 for Parkinson's disease. Experimental & molecular medicine, 58(4), 993.

Uno N, et al. (2024) Microcell-mediated chromosome transfer between non-identical human iPSCs. Molecular therapy. Nucleic acids, 35(4), 102382.

Ueda T, et al. (2023) Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nature biomedical engineering, 7(1), 24.

Sanchez-Martin A, et al. (2023) Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 165, 115209.

Nishitani-Isa M, et al. (2022) Trapping of CDC42 C-terminal variants in the Golgi drives pyrin inflammasome hyperactivation. The Journal of experimental medicine, 219(6).

Fukuta M, et al. (2021) Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model. Lupus science & medicine, 8(1).

Yokota M, et al. (2021) Establishment of an in vitro model for analyzing mitochondrial ultrastructure in PRKN-mutated patient iPSC-derived dopaminergic neurons. Molecular brain, 14(1), 58.

Takahashi K, et al. (2020) Critical Roles of Translation Initiation and RNA Uridylation in Endogenous Retroviral Expression and Neural Differentiation in Pluripotent Stem Cells. Cell reports, 31(9), 107715.

Hirosawa M, et al. (2019) Cell-Type-Specific CRISPR Activation with MicroRNA-Responsive AcrllA4 Switch. ACS synthetic biology, 8(7), 1575.

Ishii T, et al. (2019) In Vitro Modeling of the Bipolar Disorder and Schizophrenia Using Patient-Derived Induced Pluripotent Stem Cells with Copy Number Variations of PCDH15 and RELN. eNeuro, 6(5).

Sasaki-Honda M, et al. (2018) A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4. Human molecular genetics, 27(23), 4024.

Hirosawa M, et al. (2017) Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. Nucleic acids research, 45(13), e118.

Arsenault PR, et al. (2016) Identification of Small-Molecule PHD2 Zinc Finger Inhibitors that Activate Hypoxia Inducible Factor. Chembiochem : a European journal of chemical biology, 17(24), 2316.

Li HL, et al. (2016) Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system. Methods (San Diego, Calif.), 101, 27.